Zoledronate Administration Lowers Vertebral Fracture Incidence in Younger Postmenopausal Women Lacking Osteoporosis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Zoledronate Administration Lowers Vertebral Fracture Incidence in Younger Postmenopausal Women Lacking Osteoporosis

  • By

  • Christian Hannah

  • Jason T. Alexander

  • Samuel W. Trump

  • April 27, 2026

Share

  • 1

    Zoledronate administration significantly reduces vertebral fracture incidence in younger postmenopausal women without osteoporosis.

  • 2

    The study involved 1,054 women aged 50 to 60, with a follow-up period of 10 years and a primary outcome of new morphometric vertebral fractures.

  • 3

    The number needed to treat to prevent one vertebral fracture was 22 in the zoledronate-placebo group over the 10-year period.

  • 4

    Both zoledronate treatment groups exhibited increased bone density and lower bone turnover markers compared to the placebo group.

  • 5

    Adverse events were low, with no atypical femur fractures or osteonecrosis of the jaw reported in the study.

Original Source(s)

Zoledronate Administration Lowers Vertebral Fracture Incidence in Younger Postmenopausal Women Lacking Osteoporosis

  • by Christian Hannah, Jason T. Alexander, Samuel W. Trump

  • April 27, 2026

Related Content

Association of Bone Mass, Falls, and Vertebral Fractures in Older Patients on Hemodialysis: The Role of Comprehensive Geriatric Assessment

Fracture Risk Associated With Long-Term Discontinuation of Postmenopausal Osteoporosis Treatment: A French Population-Based Study Using National Claims Data (Système National des Données de Santé)

Heart Failure is an Independent Risk Factor for Incident Hip, Proximal Humerus, and Wrist Fractures in a High-Risk Older Population